Advocacy Groups Push ICER To Reevaluate Migraine Drug Analysis

By Ariel Cohen / February 27, 2020 at 3:25 PM

Policy and patient advocacy groups are calling on the Institute for Clinical and Economic Review to rerun its analysis on the cost-effectiveness of three drugs to treat acute migraines, using ICER’s updated framework that considers societal factors.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.